Group 1 - NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases [4] - The company is developing DA-1726 for obesity treatment and DA-1241 for Metabolic Dysfunction-Associated Steatohepatitis (MASH) [4] - DA-1726 is a novel oxyntomodulin (OXM) analogue acting as a dual agonist for glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), potentially leading to superior weight loss compared to selective GLP1R agonists [4] - DA-1241 is a G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides and has shown positive effects on liver inflammation, lipid metabolism, and glucose control in preclinical studies [4] Group 2 - Management will participate in the H.C. Wainwright 8th Annual MASH Virtual Conference on October 7, presenting a company overview [1] - One-on-one meetings will be available during the conference for interested investors [2] - The company will also participate in the Maxim Healthcare Virtual Summit from October 15-17, with a virtual fireside chat featuring the CEO and CFO [3]
NeuroBo Pharmaceuticals to Participate in Investor Conferences in October